You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股表現》和譽(02256.HK)暗盤高開1.9%報12.7元
阿思達克 10-12 16:16
根據輝立交易平臺顯示,明天(13日)掛牌的和譽-B(02256.HK)暗盤高開1.9%報12.7元欠承接,掉頭低見10.66元,現報12元,較上市價12.46元,低3.7%,成交1.2萬股。 和譽是一家臨牀階段仍未有盈利的生物製藥公司,其致力於發現及開發創新且差異化的小分子腫瘤療法,並已戰略性地設計及開發由14個專注於腫瘤學的候選藥物組成的管線,包括五種處於臨牀階段的候選藥物。是次上市共發售近1.41億股,並已引入包括LAV、UBS基金、Epsomite、淡馬錫旗下Aranda及貝萊德等11家基石投資者(設6個月禁售期)合共認購7,969.8萬股;10%公開發售獲4.64倍超購,認購一手中籤率13.22%;股份以招股範圍(12.16-12.46元)上限定價,料集資淨額約16.05億元,主要用於進行中的及未來的研發,包括核心候選產品ABSK011和ABSK091的臨牀試驗及未來商業化、持續開發研發平臺及研發新型臨牀前候選藥物、以及建造製造設施和租用新研發設施等。上市聯席保薦人分別爲大摩及摩通。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account